Rating Change
HC Wainwright & Co. reiterated its Buy rating on Viridian Therapeutics, Inc. (NASDAQ:VRDN) on November 05, 2026.
reiterateNASDAQ:VRDN
HC Wainwright & Co. Reiterates Buy Rating on Viridian Therapeutics, Inc. (VRDN)
HC Wainwright & Co. reiterated its Buy rating on Viridian Therapeutics, Inc.
At publication ·
What changed
Viridian Therapeutics, Inc. (NASDAQ:VRDN) · reiterate
- Firm
- HC Wainwright & Co.
- Rating
- Buy to Buy
- Price at event
- $28.77
- Market capitalization
- $2.6B
At a glance
Key takeaways
- HC Wainwright & Co. reiterated a Buy rating on Viridian Therapeutics (VRDN) on November 5, 2026, with the stock trading at $28.77 and a market capitalization of $2.6 billion.
Market Context
Viridian Therapeutics, Inc. operates in the Healthcare sector. The stock currently trades at $28.77 with a market capitalization of $2.6B.
Analyst coverage from HC Wainwright & Co. provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Viridian Therapeutics, Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Viridian Therapeutics, Inc.
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Nov 05, 2026 | Evercore ISI Group | Outperform | N/A |
| Nov 05, 2026 | Wedbush | Outperform | N/A |
| Nov 05, 2026 | HC Wainwright & Co. | Buy | N/A |
| Nov 04, 2026 | Needham | Buy | N/A |
| Sep 22, 2026 | RBC Capital | Outperform | N/A |
Related Tools: Analyst Ratings Dashboard | View VRDN Stock Page
Frequently Asked Questions
What does the Buy rating mean for VRDN?
A rating of Buy from HC Wainwright & Co. reflects the analyst's outlook on Viridian Therapeutics, Inc. (NASDAQ:VRDN). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the VRDN forecast page.